Naiyer Rizvi

CMO at Synthekine

Dr. Rizvi is an internationally recognized leader in cancer immunotherapy drug development whose clinical research has helped deliver FDA approvals of several landmark immunotherapies, including nivolumab in squamous lung cancer and pembrolizumab in non-small cell lung cancer. He will lead Synthekine’s efforts in advancing its maturing pipeline through clinical investigation.

As a medical oncologist and expert in clinical immuno-oncology, Dr. Rizvi’s research into mechanisms of sensitivity and resistance to immunotherapy has laid the foundation to the understanding of clinical responses to immune checkpoint inhibitors. Dr. Rizvi conducted clinical studies of novel immunotherapy drugs and immunotherapy combinations, including the landmark study to demonstrate a correlation between mutations and neoantigens with durable benefit to the immune-checkpoint blockade. His work has been published in leading journals including Science, Nature, and the New England Journal of Medicine.

Dr. Rizvi most recently served as the Price Family Professor of Medicine, Director of Thoracic Oncology, and Co-Director of Cancer Immunotherapy at Columbia University Medical Center. In addition, Dr. Rizvi was recently Research Director of the Price Family Comprehensive Center for Chest Care at New York-Presbyterian Hospital. Dr. Rizvi received his medical doctorate from the University of Manitoba Faculty of Medicine and completed his residency training at the University of Manitoba Affiliated Hospital and fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School. He was a co-founder of Gritstone Oncology.

Links

Previous companies

Georgetown University logo
Memorial Sloan - Kettering Cancer Center logo
Columbia University logo

Timeline

  • CMO

    May, 2021 - present